使用肿瘤浸润淋巴细胞 (TIL) 细胞疗法治疗乳腺纺锤形细胞癌：病例报告。

IF 2.3 4区医学 Q3 ONCOLOGY Current cancer drug targets Pub Date : 2024-07-02 DOI:10.2174/0115680096294250240604075529

Yiyin Tang, Li Li, Guoqin Wang, Dan Liu, Yinju Yang, Jinyan Yang, Lin Hua, Ruilei Li, Chunlei Ge, Hong Yao, Ke Li

{"title":"使用肿瘤浸润淋巴细胞 (TIL) 细胞疗法治疗乳腺纺锤形细胞癌：病例报告。","authors":"Yiyin Tang, Li Li, Guoqin Wang, Dan Liu, Yinju Yang, Jinyan Yang, Lin Hua, Ruilei Li, Chunlei Ge, Hong Yao, Ke Li","doi":"10.2174/0115680096294250240604075529","DOIUrl":null,"url":null,"abstract":"The article has been withdrawn at the request of the authors.Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.phpBentham science disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simul-taneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been pub-lished elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"WITHDRAWN: Use of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy for Spindle Cell Carcinoma of the Breast: A Case Report\",\"authors\":\"Yiyin Tang, Li Li, Guoqin Wang, Dan Liu, Yinju Yang, Jinyan Yang, Lin Hua, Ruilei Li, Chunlei Ge, Hong Yao, Ke Li\",\"doi\":\"10.2174/0115680096294250240604075529\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The article has been withdrawn at the request of the authors.Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.phpBentham science disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simul-taneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been pub-lished elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.\",\"PeriodicalId\":10816,\"journal\":{\"name\":\"Current cancer drug targets\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-07-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current cancer drug targets\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0115680096294250240604075529\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096294250240604075529","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：乳腺纺锤形细胞癌（SCC）是一种罕见的移行细胞癌，具有预后差、复发率高和远处转移等特点。乳腺切除术、化疗、放疗和内分泌治疗是首选的治疗方法。肿瘤浸润淋巴细胞（TIL）疗法是利用患者实体瘤微环境中的免疫细胞来消灭癌细胞，在治疗晚期实体瘤方面取得了良好的效果。然而，将其用于乳腺 SCC 的病例尚未见报道：在此，我们介绍一例将 TIL 治疗与个体化化疗和内分泌治疗相结合治疗乳腺 SCC 的病例。一名 36 岁的中国女性因左侧乳房可触及结节（32 毫米）而就诊。根据乳腺活检和手术标本的组织学和免疫组化分析，她被诊断为乳腺 SCC（IIA 期）。乳房切除术后，患者同时接受了个性化化疗、TIL 治疗和内分泌治疗。她在治疗期间没有出现严重的副作用，随访至少 14 个月后也没有出现局部复发或远处转移：据我们所知，这是第一例证明乳房切除术后 TIL 治疗联合化疗/内分泌治疗对乳腺 SCC 安全有效的病例报告。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

WITHDRAWN: Use of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy for Spindle Cell Carcinoma of the Breast: A Case Report

The article has been withdrawn at the request of the authors.

Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.

The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php

Bentham science disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simul-taneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been pub-lished elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current cancer drug targets 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

105

审稿时长

1 months

期刊介绍： Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.